ClinicalTrials.gg
CompletedNCT03939702Updated Oct 4, 2019

Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants

A Phase 1 interventional study of BMS-986177 in Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-04.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Health services research

From the registry’s dates

  • Primary completion was Jul 2019, 7 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Thrombosis by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Thrombosis · Bristol-Myers Squibb.

Enrollment
18th of 19
9 · median 42
Started
2019
the only one that year
Phase 1
13 of 19
none open now
Registered
18th of 19
by date

Among the 19 studies in Thrombosis by Bristol-Myers Squibb, this one is the 18th largest by enrollment, is the only one that started in 2019, is one of 13 in phase 1, and was the 18th registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

None of the 19 studies in Thrombosis by Bristol-Myers Squibb is open now. The open studies under Thrombosis, anywhere →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Thrombosis by Bristol-Myers Squibb as a file.
02

Study summary

This is an ADME study. Human radiolabeled mass balance studies are performed as part of drug development to obtain information about the absorption, distribution, metabolism, and excretion (ADME) of a study treatment. The goals of human ADME studies include the assessment of absorption, distribution, routes and rates of excretion, mass balance, and metabolite profile and identification.

03

Conditions studied

  • Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed ICF
  • Healthy Male
  • of 18.0 to 32.0 kg/m2, inclusive.
  • Agreement to use approved for 94 days post treatment
  • Agreement to not donate sperm for 94 days post treatment

Exclusion criteria

Exclusion Criteria:

  • Acute or chronic illness
  • GI disease current or recent
  • History of dizziness or recurring headaches
  • Head injury within last 2 years
  • GI surgery
  • History or evidence of abnormal bleeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Active comparator
    Non-Bile Collection

    On Day 1, all participants will receive a single oral solution dose of 200 mg \[14C\] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12

    Drug: BMS-986177

  • Active comparator
    Bile Collection

    On Day 1, all participants will receive a single oral solution dose of 200 mg \[14C\] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Approximately 1 hour after study drug administration, an ND tube may be positioned in approximately 3 selected participants for collection of bile.Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12

    Drug: BMS-986177

Interventions

  • An orally administered anticoagulant to prevent and treat thromboembolic events

06

What researchers measure

Primary outcomes

  1. Assess PK Cmax of a dose of [14C]BMS-986177

    Cmax

    Time frame: Day 1-12

  2. Assess PK AUC(INF) of a dose of [14C]BMS-986177

    AUC(INF)

    Time frame: Day 1-12

  3. Assess PK AUC(0-T) of a dose of [14C]BMS-986177

    AUC(0-T)

    Time frame: Day 1-12

  4. Assess PK Tmax of a dose of [14C]BMS-986177

    Tmax

    Time frame: Day 1-12

  5. Assess PK T-HALF of a dose of [14C]BMS-986177

    T-HALF

    Time frame: Day 1-12

  6. Assess PK CL/F of a dose of [14C]BMS-986177

    Time frame: Day 1-12

  7. Assess PK Vz/F of a dose of [14C]BMS-986177

    Vz/F

    Time frame: Day 1-12

  8. Assess PK AUC of a dose of [14C]BMS-986177

    AUC(BMS-986177)

    Time frame: Day 1-12

  9. Assess PK AUC(TRA) of a dose of [14C]BMS-986177

    AUC(TRA)

    Time frame: Day 1-12

  10. Assess PK Plasma AUC(TRA) of a dose of [14C]BMS-986177

    Plasma AUC(TRA)

    Time frame: Day 1-12

  11. Assess PK Blood AUC(TRA) of a dose of [14C]BMS-986177

    Blood AUC(TRA)

    Time frame: Day 1-12

  12. Assess the CLR of [14C]BMS-986177

    CLR

    Time frame: Day 1-12

  13. Assess the %UR of [14C]BMS-986177

    %UR

    Time frame: Day 1-12

  14. Assess the %FE of [14C]BMS-986177

    %FE

    Time frame: Day 1-12

  15. Assess the %BE of [14C]BMS-986177

    %BE (if applicable)

    Time frame: Day 1-12

  16. Assess the %Total recovery of [14C]BMS-986177

    %Total recovery

    Time frame: Day 1-12

Secondary outcomes

  1. Asess the Incidence of AEs of a single oral dose of 200 mg [14C] BMS-986177

    Incidence of AEs

    Time frame: Day 1-12

  2. Asess the Incidence of SAEs of a single oral dose of 200 mg [14C] BMS-986177

    Incidence of SAEs

    Time frame: Day 1-12

  3. Asess the Incidence of AEs leading to discontinuation of a single oral dose of 200 mg [14C] BMS-986177

    Incidence of AEs leading to discontinuation

    Time frame: Day 1-12

  4. Assess the vital signs of a subject dosed with single oral dose of 200 mg [14C] BMS-986177

    results of vital sign examination

    Time frame: Day 1-12

  5. Assess the ECGs of subjects dosed with single oral dose of 200 mg [14C] BMS-986177

    ECG physical examinations

    Time frame: Day 1-12

  6. Assess the clinical lab tests of a single oral dose of 200 mg [14C] BMS-986177

    Results of Clinical laboratory tests

    Time frame: Day 1-12

07

Study locations

1 site
  • Covance Clinical Research Unit, Inc.
    Madison, Wisconsin 53704, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Jul 2019, 2 months.

Of 30 phase 1 interventional studies under Thrombosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2019
First posted
May 7, 2019
StartActual
May 2, 2019
Primary completionActual
Jul 11, 2019
CompletionActual
Jul 11, 2019
Last update
Oct 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03939702
Responsible party
Sponsor
First posted
May 7, 2019
Start date
May 2, 2019
Primary completion
Jul 11, 2019
Completion
Jul 11, 2019
Last update
Oct 4, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milvexian

Start the discussion